English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduThe University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Tag: Nk Cells
Nanoparticles restore efficiency in exhausted immune cells killing cancer
A novel study led by Prof. Mira Barda-Saad and her research team at the Goodman Faculty of Life Sciences at Bar-Ilan University has unveiled a novel method to rejuvenate natural killer (NK) cells in the fight against cancer. The study, published on the cover of The EMBO Journal, addresses a critical challenge in cancer immunotherapy — NK cell exhaustion.
NK cells expressing interleukin-21 show promising antitumor activity in glioblastoma cells
Natural killer (NK) cells engineered to express interleukin-21 (IL-21) demonstrated sustained antitumor activity against glioblastoma stem cell-like cells (GSCs) both in vitro and in vivo, according to new research from The University of Texas MD Anderson Cancer Center.
Short On Time? A 15-minute Workout May Help Boost Your Immune System
Exercising at moderate intensity for just 15 minutes may be all that is needed to boost immunity by increasing levels of natural killer (NK) cells. Researchers will present their work this week at the American Physiology Summit in Long Beach, California.
An extra X chromosome-linked gene may explain decreased viral infection severity in females
Researchers may have found why viral infections hit males more severely than females. They found that female mouse and human NK cells have an extra copy of an X chromosome-linked gene called UTX. UTX acts as an epigenetic regulator to boost NK cell anti-viral function, while repressing NK cell numbers.
MD Anderson and KKR-backed Replay form new product company Syena to pioneer first-in-class TCR NK cell therapy
MD Anderson and Replay announced the launch of Syena, a new oncology-focused product company pioneering T cell receptor (TCR) natural killer (NK) cell therapies.
MD Anderson researchers present cellular therapy advances at the 2022 ASCO Annual Meeting
Promising clinical results with cellular therapies for patients with blood cancers highlight advances being presented by researchers from The University of Texas MD Anderson Cancer Center at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
These findings include long-term outcomes of patients receiving an infusion of brexucabtagene autoleucel (KTE-X19) for mantle cell lymphoma, efficacy of gamma delta CAR T therapy for aggressive B-cell lymphoma and responses of umbilical cord blood-derived expanded natural killer cells when given together with combination therapy before stem cell transplant.